Stockscreener 앱 받기
107.19
3.86%
4.03
전일 마감가:
$103.16
열려 있는:
$107.06
하루 거래량:
381.05K
Relative Volume:
0.05
시가총액:
$158.51B
수익:
$17.55B
순이익/손실:
$2.03B
주가수익비율:
78.24
EPS:
1.37
순현금흐름:
$2.72B
1주 성능:
+3.83%
1개월 성능:
+4.67%
6개월 성능:
+5.42%
1년 성능:
+36.33%
1일 변동 폭
$105.75
$108.94
1주일 범위
$102.26
$108.94
52주 변동 폭
$71.88
$108.94
보스턴사이언티픽 Stock (BSX) Company Profile
명칭
Boston Scientific Corp
전화
508-683-4000
주소
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
BSX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
107.14 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
ABT
Abbott Laboratories
|
124.51 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
SYK
Stryker Corp
|
399.17 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.82 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.00 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
보스턴사이언티픽 Stock (BSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 개시 | Leerink Partners | Outperform |
| 2025-04-16 | 업그레이드 | Needham | Hold → Buy |
| 2025-01-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-10-18 | 다운그레이드 | Needham | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-01 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-06-30 | 개시 | CL King | Buy |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-20 | 재개 | Citigroup | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-06 | 개시 | Wolfe Research | Outperform |
| 2022-05-27 | 업그레이드 | Needham | Hold → Buy |
| 2022-04-13 | 재개 | Truist | Buy |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-05-26 | 다운그레이드 | Needham | Buy → Hold |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2020-09-17 | 개시 | Truist | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Peer Perform |
| 2020-04-22 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Buy |
| 2019-12-30 | 재확인 | Cowen | Outperform |
| 2019-12-19 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2019-09-05 | 재개 | JP Morgan | Overweight |
| 2019-09-03 | 재개 | Barclays | Overweight |
| 2019-05-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-11-28 | 개시 | UBS | Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-10-02 | 재확인 | Morgan Stanley | Overweight |
| 2018-09-07 | 재확인 | Needham | Strong Buy |
| 2018-09-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-07-06 | 재확인 | Needham | Strong Buy |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-04-26 | 재확인 | Needham | Strong Buy |
모두보기
보스턴사이언티픽 주식(BSX)의 최신 뉴스
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up - The Globe and Mail
Boston Scientific stock price target raised to $120 by BofA Securities - Investing.com
Boston Scientific (BSX) Price Target Increased by BofA Analyst | - GuruFocus
Boston Scientific lifts annual profit forecast, sees smaller tariff impact - Reuters
Boston Scientific lifts annual profit forecast, sees smaller tariff impact By Reuters - Investing.com
Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance - inkl
Boston Scientific Lifts Outlook On Cardiovascular Revenue Growth - Finimize
Boston Scientific stock hits all-time high at 107.76 USD By Investing.com - Investing.com UK
Earnings call transcript: Boston Scientific Q2 2025 beats expectations, stock rises - Investing.com
Boston Scientific lifts annual profit view on steady heart devices demand - Reuters
Boston Scientific: Q2 Earnings Snapshot - CTPost
Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates - Nasdaq
Boston Scientific increases full-year guidance after Q2 beats - MassDevice
Boston Scientific Q2 2025 Earnings Outperform Guidance with 22.8% Sales Growth 13.6% EPS Rise - AInvest
Boston Scientific Boosts FY25 OutlookUpdate - Nasdaq
Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Expectations - GuruFocus
Boston Scientific Corp (BSX) Q2 2025 Earnings: EPS of $0.53 Beats Estimate, Revenue Surges to $5.061 Billion - GuruFocus
Boston Scientific Q2 2025 slides: 22.8% sales growth fueled by Electrophysiology surge - Investing.com
Boston Scientific trumps top and bottom-line forecasts, issues upbeat 2025 guide - Investing.com
Boston Scientific earnings beat by $0.02, revenue topped estimates - Investing.com UK
Boston Scientific Q2 2025 Financial Results - TradingView
Boston Scientific announces results for second quarter 2025 - Financial Times
Is Boston Scientific Corporation a good long term investmentRobust investment performance - jammulinksnews.com
Boston Scientific (BSX) Anticipates Robust Q2 Earnings Growth - GuruFocus
FDA expands Boston Sci’s Watchman label to post-ablation - BioWorld MedTech
Raymond James maintains Strong Buy on Boston Scientific stock - Investing.com
Boston Scientific Watchman wins FDA expansion for post-ablation patients - MassDevice
Boston Scientific stock set to beat Q2 estimates, says TD Cowen - Investing.com
Boston Scientific: Strong Growth Potential and Positive Outlook Justify Buy Rating - TipRanks
What analysts say about Boston Scientific Corporation stockBreakthrough stock performance - printweek.in
Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS - Yahoo Finance
Boston Scientific Corp (BSX) Secures FDA Labeling Expansion for FARAPULSE Pulsed Field Ablation (PFA) System - MSN
Boston Scientific’s Innovation Drive Keeps The Stock Climbing - Finimize
Lobbying Update: $570,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed - Nasdaq
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Is Boston Scientific Corporation (NYSE:BSX) Worth US$103 Based On Its Intrinsic Value? - Yahoo Finance
Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings? - MSN
Boston Scientific receives US FDA approval for expanded labelling of Farapulse pulsed field ablation system - Cardiac Rhythm News
Boston Scientific (BSX): A High-Stakes Gamble on Innovation Ahead of Q2 Earnings - AInvest
Why Boston Scientific (BSX) Outpaced the Stock Market Today - Yahoo Finance
Prostate Care Market Report 2025-2031 | Medtronic, Johnson & Johnson, Boston Scientific, and Abbott Laboratories Dominate through Product Innovations, Clinical Trials, M&As, and Strategic Partnerships - Yahoo Finance
13 Best Large Cap Stocks to Buy Right Now - Insider Monkey
Boston Scientific’s (BSX) FARAPULSE Approved by FDA for Expanded Labeling - Insider Monkey
Boston Scientific (BSX) Crossed Above the 20-Day Moving Average: What That Means for Investors - Yahoo Finance
Here's How Much a $1000 Investment in Boston Scientific Made 10 Years Ago Would Be Worth Today - Yahoo Finance
North America Ureteroscopes Market Outlook Report 2018-2033 with an Overview of Key CompaniesBoston Scientific, KARL STORZ, Olympus, PENTAX Medical, and Richard Wolf - Yahoo Finance
NICE recommends pulsed field ablation tech for AFib - MassDevice
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Is It Worth Adding Boston Scientific Stock To Your Portfolio Now? - Barchart.com
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now? - Yahoo Finance
Boston Scientific (BSX) Receives a Buy from Citi - The Globe and Mail
보스턴사이언티픽 (BSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
0.96%
자본화:
|
볼륨(24시간):